Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. (Q36028324)

11 August 2017

1 reference

title

Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. (English)

1 reference

11 August 2017

main subject

liver transplantation

1 reference

1 reference

1

Bruno Roche

1 reference

11 August 2017

2

Didier Samuel

1 reference

11 August 2017

publication date

2 February 2005

1 reference

11 August 2017

published in

Transplant International

1 reference

11 August 2017

volume

17

1 reference

11 August 2017

issue

12

1 reference

11 August 2017

page(s)

746-758

1 reference

Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to the emergence of a hepatitis B YMDD escape mutant virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Liver transplantation in hepatitis delta virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Safe use of livers from donors with positive hepatitis B core antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

De novo and apparent de novo hepatitis B virus infection after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Lamivudine treatment for acute hepatitis B after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

Hepatitis B vaccination after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1432-2277.2004.TB00507.X

10.1111/J.1432-2277.2004.TB00507.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference